Key Insights
The Immuno-Oncology Assays market is poised for significant expansion, projected to reach an estimated $6.3 billion in 2025, demonstrating robust growth with a projected Compound Annual Growth Rate (CAGR) of 11.8% through 2033. This upward trajectory is primarily fueled by advancements in understanding the complex interplay between the immune system and cancer, leading to the development of novel immunotherapies. Key drivers include the increasing prevalence of various cancer types such as lung cancer, colorectal cancer, and melanoma, which are prime targets for immuno-oncology treatments. Furthermore, rising investments in research and development by leading biotechnology and pharmaceutical companies, alongside growing government initiatives to support cancer research, are significantly contributing to market expansion. The demand for sophisticated diagnostic tools that can accurately identify patient populations likely to respond to immunotherapy is also a crucial growth factor.
Immuno Oncology Assays Industry Market Size (In Billion)
Technological innovations are revolutionizing the immuno-oncology assay landscape. The market is segmented into key product categories including Reagents and Antibodies, Instruments, Software, and Consumables and Accessories, all experiencing concurrent growth. In terms of technology, Immunoassay, Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), and Flow Cytometry are prominent segments, enabling deeper insights into tumor microenvironments and immune cell activity. While the market is characterized by strong growth drivers, certain restraints such as the high cost of advanced assay development and the complex regulatory approval processes for new diagnostic tools may pose challenges. However, the overarching trend towards personalized medicine and the continuous evolution of immunotherapy further solidify the positive outlook for the immuno-oncology assays market. Leading players like Merck KGaA, F. Hoffmann-La Roche Ltd, and Thermo Fisher Scientific are at the forefront, driving innovation and expanding market reach.
Immuno Oncology Assays Industry Company Market Share
Report Title: Immuno Oncology Assays Market: Comprehensive Analysis, Growth Forecasts, and Competitive Landscape (2019–2033)
Report Description:
Gain unparalleled insights into the dynamic Immuno Oncology Assays market with this definitive report. Spanning a comprehensive study period from 2019 to 2033, with a deep dive into the base year 2025 and an extensive forecast period of 2025–2033, this report meticulously analyzes market size, growth drivers, segmentation, and the competitive ecosystem. Explore the intricate interplay of technological advancements, regulatory landscapes, and evolving therapeutic strategies that are shaping the future of cancer immunotherapy. This report provides critical data for stakeholders including biopharmaceutical companies, diagnostic kit manufacturers, research institutions, and investors seeking to capitalize on the burgeoning immuno-oncology sector. Understand the nuances of parent and child market segments, identify emerging opportunities, and navigate the competitive arena with expert analysis.
Immuno Oncology Assays Industry Market Dynamics & Structure
The Immuno Oncology Assays market is characterized by moderate to high concentration, driven by significant technological innovation and stringent regulatory frameworks, particularly in the companion diagnostics (CDx) space. Key drivers include the increasing understanding of tumor-immune interactions and the demand for personalized cancer therapies. Competitive product substitutes are evolving rapidly, with advancements in liquid biopsy and multi-omic approaches posing challenges to traditional assay methodologies. End-user demographics are expanding to include not only leading oncologists and research institutions but also a growing number of molecular pathology labs. Mergers and acquisitions (M&A) are a prevalent trend, with companies seeking to consolidate their portfolios and gain access to novel technologies or market segments. For instance, the acquisition of specialized assay developers by larger diagnostic companies aims to strengthen their offerings in areas like biomarker identification and patient stratification. Innovation barriers include the high cost of R&D, lengthy validation processes, and the need for robust clinical evidence to support assay utility. The market is projected to witness increased collaboration between assay developers and pharmaceutical companies to streamline drug development and patient selection processes. The intricate relationship between parent markets, such as broader in-vitro diagnostics, and child markets, like specific biomarker assays for lung cancer, is crucial for understanding market dynamics.
Immuno Oncology Assays Industry Growth Trends & Insights
The Immuno Oncology Assays market is poised for substantial growth, driven by an escalating global cancer burden and the paradigm shift towards targeted immunotherapies. The market size is projected to grow at a significant Compound Annual Growth Rate (CAGR) of approximately 15.5% from 2025 to 2033. Adoption rates for advanced immuno-oncology assays, particularly those identifying predictive biomarkers for immune checkpoint inhibitors and CAR T-cell therapies, are rapidly increasing. Technological disruptions, such as the integration of artificial intelligence (AI) in assay data analysis and the advancement of multiplex assay platforms, are revolutionizing diagnostic capabilities. Consumer behavior shifts are evident, with oncologists and patients increasingly demanding more precise and personalized treatment strategies, thereby fueling the demand for sophisticated diagnostic tools. The market penetration of these assays is expected to deepen across developed and emerging economies as regulatory bodies streamline approval processes and reimbursement policies become more favorable. The interplay between parent market growth, for example, the expansion of the global diagnostics market, and the specialized growth within immuno-oncology assay sub-segments is a key indicator of market vitality. Understanding the adoption curves for different technologies, such as Next-Generation Sequencing (NGS) for comprehensive genomic profiling versus traditional Immunoassays for single biomarker detection, provides critical insights into market evolution. The increasing focus on early cancer detection and recurrence monitoring further amplifies the demand for sensitive and specific immuno-oncology assays.
Dominant Regions, Countries, or Segments in Immuno Oncology Assays Industry
North America currently stands as the dominant region in the Immuno Oncology Assays market, driven by a robust healthcare infrastructure, significant investment in R&D, and a high prevalence of cancer. The United States, in particular, leads in terms of market share, owing to early adoption of advanced diagnostics, favorable regulatory environments, and the presence of key market players. From a Product segmentation perspective, Reagents and Antibodies is the largest and fastest-growing segment, essential for the development and performance of all types of immuno-oncology assays. The Technology segment is witnessing considerable traction in NGS, which offers comprehensive genomic profiling and biomarker identification, crucial for personalized medicine. However, Immunoassays continue to hold a significant share due to their established utility, cost-effectiveness for specific applications, and widespread availability, particularly for protein-based biomarkers. In terms of Indication, Lung Cancer dominates the market, reflecting its high incidence and the extensive research into immunotherapy targets for this disease. The development of companion diagnostics for lung cancer therapies has significantly propelled this segment. Key drivers for North America's dominance include government funding for cancer research, strong collaboration between academia and industry, and established reimbursement pathways for advanced diagnostic tests. Market share within this region is heavily influenced by the demand for novel biomarker detection, especially for indications like non-small cell lung cancer (NSCLC) and melanoma. The growth potential of this region is further bolstered by an aging population and increasing awareness about the benefits of early cancer diagnosis and targeted therapies. The continuous flow of new drugs requiring specific diagnostic tests ensures sustained demand.
Immuno Oncology Assays Industry Product Landscape
The product landscape for Immuno Oncology Assays is characterized by rapid innovation and diversification. Key product developments focus on enhancing assay sensitivity, specificity, and multiplexing capabilities. Innovations include the development of highly specific antibodies for novel tumor antigens, advanced reagent formulations for improved assay performance, and integrated instrument platforms that streamline complex workflows. Applications range from the identification of predictive biomarkers for immunotherapy response to monitoring disease progression and recurrence. Performance metrics such as limit of detection, assay throughput, and turnaround time are continuously being improved. Unique selling propositions often lie in the ability of assays to detect multiple biomarkers simultaneously, enabling a more comprehensive understanding of a patient's tumor microenvironment and potential response to various immunotherapies. Technological advancements are also focused on making assays more accessible and cost-effective, particularly for routine clinical use.
Key Drivers, Barriers & Challenges in Immuno Oncology Assays Industry
Key Drivers:
- Advancements in Cancer Immunotherapy: The surge in immunotherapy drugs (e.g., checkpoint inhibitors, CAR T-cell therapies) directly fuels the demand for assays that identify patient eligibility and predict treatment response.
- Growing Cancer Incidence and Prevalence: The increasing global burden of cancer necessitates more effective diagnostic and prognostic tools, driving innovation in immuno-oncology assays.
- Personalized Medicine Trend: The shift towards tailored treatment strategies requires precise biomarkers for patient stratification, boosting the adoption of advanced immuno-oncology assays.
- Technological Innovations: Developments in technologies like NGS, digital PCR, and advanced flow cytometry enable the detection of novel biomarkers and improve assay performance.
Barriers & Challenges:
- High R&D Costs and Long Validation Times: Developing and validating new immuno-oncology assays is expensive and time-consuming, requiring extensive clinical trials.
- Regulatory Hurdles and Reimbursement Issues: Navigating complex regulatory pathways for assay approval and securing adequate reimbursement from payers can be challenging, impacting market accessibility.
- Complex Tumor Microenvironment: The intricate nature of the tumor microenvironment and the dynamic interplay of various immune cells and factors make biomarker discovery and assay development complex.
- Data Interpretation and Standardization: Standardizing assay protocols and ensuring consistent interpretation of complex data across different labs remains a significant challenge.
- Supply Chain Disruptions: Reliance on specialized reagents and components can lead to supply chain vulnerabilities, impacting production and availability.
Emerging Opportunities in Immuno Oncology Assays Industry
Emerging opportunities in the Immuno Oncology Assays industry lie in the development of novel biomarkers for early cancer detection and recurrence monitoring, particularly for less common cancer types. The expansion of liquid biopsy technologies presents a significant opportunity for non-invasive diagnostic approaches. Furthermore, the integration of AI and machine learning for analyzing complex assay data offers potential for more accurate patient stratification and treatment selection. Untapped markets in developing economies, as healthcare infrastructure improves, also represent a growth avenue. Innovations in multiplex assay platforms that can assess a broad panel of immune-related biomarkers simultaneously are also gaining traction.
Growth Accelerators in the Immuno Oncology Assays Industry Industry
Growth accelerators for the Immuno Oncology Assays industry include sustained investment in cancer research and development, leading to the discovery of new therapeutic targets and corresponding diagnostic biomarkers. Strategic partnerships between diagnostic companies and pharmaceutical firms are crucial for co-development and commercialization of companion diagnostics. Market expansion strategies, particularly in emerging economies, coupled with favorable government policies supporting precision medicine initiatives, will further propel growth. Technological breakthroughs in areas like single-cell analysis and spatial transcriptomics are expected to unlock new diagnostic frontiers.
Key Players Shaping the Immuno Oncology Assays Industry Market
- Merck KGaA
- F Hoffmann-La Roche Ltd
- HTG Molecular Diagnostics Inc
- Agilent Technologies Inc
- Crown Bioscience
- PerkinElmer Inc
- Illumina Inc
- Thermo Fisher Scientific
- InSphero
Notable Milestones in Immuno Oncology Assays Industry Sector
- September 2022: The US FDA approved Thermo Fisher Scientific's Oncomine Dx Target Test as a companion diagnostic (CDx) aid in selecting patients with RET-fusion positive locally advanced or metastatic non-small cell lung cancer (NSCLC), RET-fusion positive advanced or metastatic thyroid cancer, and RET-mutation positive advanced or metastatic medullary thyroid cancer (MTC) who may be eligible for treatment with Lilly's Retevmo (selpercatinib).
- June 2022: Agilent Technologies Inc. received approval from the South Korea Ministry of Food and Drug Safety (MFDS) for the company's PD-L1 IHC 22C3 pharmDx as a companion diagnostic (CDx) to identify patients with non-small cell lung cancer (NSCLC) suitable for first-line monotherapy with KEYTRUDA (pembrolizumab) on the Dako Omnis platform.
In-Depth Immuno Oncology Assays Industry Market Outlook
The Immuno Oncology Assays market outlook is exceptionally robust, driven by ongoing advancements in cancer immunotherapy and the increasing demand for personalized treatment strategies. Growth accelerators, such as the continuous discovery of novel biomarkers and the expansion of companion diagnostics into new cancer indications, will significantly contribute to market expansion. Strategic collaborations between assay developers, pharmaceutical companies, and academic institutions are poised to streamline the development and adoption of these critical diagnostic tools. The increasing focus on early cancer detection and the utilization of liquid biopsies will unlock new market segments. Furthermore, favorable regulatory landscapes and evolving reimbursement policies in key markets are expected to further fuel market penetration and overall growth potential.
Immuno Oncology Assays Industry Segmentation
-
1. Product
- 1.1. Reagents and Antibodies
- 1.2. Instruments
- 1.3. Software
- 1.4. Consumables and Accessories
-
2. Technology
- 2.1. Immunoassay
- 2.2. PCR
- 2.3. NGS
- 2.4. Flow Cytometry
- 2.5. Other Technologies
-
3. Indication
- 3.1. Lung Cancer
- 3.2. Colorectal Cancer
- 3.3. Melanoma
- 3.4. Other Cancers
Immuno Oncology Assays Industry Segmentation By Geography
-
1. North America
- 1.1. United States
- 1.2. Canada
- 1.3. Mexico
-
2. Europe
- 2.1. Germany
- 2.2. United Kingdom
- 2.3. France
- 2.4. Italy
- 2.5. Spain
- 2.6. Rest of Europe
-
3. Asia Pacific
- 3.1. China
- 3.2. Japan
- 3.3. India
- 3.4. Australia
- 3.5. South Korea
- 3.6. Rest of Asia Pacific
-
4. Middle East and Africa
- 4.1. GCC
- 4.2. South Africa
- 4.3. Rest of Middle East and Africa
-
5. South America
- 5.1. Brazil
- 5.2. Argentina
- 5.3. Rest of South America
Immuno Oncology Assays Industry Regional Market Share
Geographic Coverage of Immuno Oncology Assays Industry
Immuno Oncology Assays Industry REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2020-2034 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026-2034 |
| Historical Period | 2020-2025 |
| Growth Rate | CAGR of 11.8% from 2020-2034 |
| Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Rising Incidence of Cancer Globally; Increasing Adoption of Targeted Therapy
- 3.3. Market Restrains
- 3.3.1. Unfavorable Regulatory and Reimbursement Scenario
- 3.4. Market Trends
- 3.4.1. Immunoassay Segment is Expected to Have Significant Share in the Market Over the Forecast Period
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Global Immuno Oncology Assays Industry Analysis, Insights and Forecast, 2020-2032
- 5.1. Market Analysis, Insights and Forecast - by Product
- 5.1.1. Reagents and Antibodies
- 5.1.2. Instruments
- 5.1.3. Software
- 5.1.4. Consumables and Accessories
- 5.2. Market Analysis, Insights and Forecast - by Technology
- 5.2.1. Immunoassay
- 5.2.2. PCR
- 5.2.3. NGS
- 5.2.4. Flow Cytometry
- 5.2.5. Other Technologies
- 5.3. Market Analysis, Insights and Forecast - by Indication
- 5.3.1. Lung Cancer
- 5.3.2. Colorectal Cancer
- 5.3.3. Melanoma
- 5.3.4. Other Cancers
- 5.4. Market Analysis, Insights and Forecast - by Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Middle East and Africa
- 5.4.5. South America
- 5.1. Market Analysis, Insights and Forecast - by Product
- 6. North America Immuno Oncology Assays Industry Analysis, Insights and Forecast, 2020-2032
- 6.1. Market Analysis, Insights and Forecast - by Product
- 6.1.1. Reagents and Antibodies
- 6.1.2. Instruments
- 6.1.3. Software
- 6.1.4. Consumables and Accessories
- 6.2. Market Analysis, Insights and Forecast - by Technology
- 6.2.1. Immunoassay
- 6.2.2. PCR
- 6.2.3. NGS
- 6.2.4. Flow Cytometry
- 6.2.5. Other Technologies
- 6.3. Market Analysis, Insights and Forecast - by Indication
- 6.3.1. Lung Cancer
- 6.3.2. Colorectal Cancer
- 6.3.3. Melanoma
- 6.3.4. Other Cancers
- 6.1. Market Analysis, Insights and Forecast - by Product
- 7. Europe Immuno Oncology Assays Industry Analysis, Insights and Forecast, 2020-2032
- 7.1. Market Analysis, Insights and Forecast - by Product
- 7.1.1. Reagents and Antibodies
- 7.1.2. Instruments
- 7.1.3. Software
- 7.1.4. Consumables and Accessories
- 7.2. Market Analysis, Insights and Forecast - by Technology
- 7.2.1. Immunoassay
- 7.2.2. PCR
- 7.2.3. NGS
- 7.2.4. Flow Cytometry
- 7.2.5. Other Technologies
- 7.3. Market Analysis, Insights and Forecast - by Indication
- 7.3.1. Lung Cancer
- 7.3.2. Colorectal Cancer
- 7.3.3. Melanoma
- 7.3.4. Other Cancers
- 7.1. Market Analysis, Insights and Forecast - by Product
- 8. Asia Pacific Immuno Oncology Assays Industry Analysis, Insights and Forecast, 2020-2032
- 8.1. Market Analysis, Insights and Forecast - by Product
- 8.1.1. Reagents and Antibodies
- 8.1.2. Instruments
- 8.1.3. Software
- 8.1.4. Consumables and Accessories
- 8.2. Market Analysis, Insights and Forecast - by Technology
- 8.2.1. Immunoassay
- 8.2.2. PCR
- 8.2.3. NGS
- 8.2.4. Flow Cytometry
- 8.2.5. Other Technologies
- 8.3. Market Analysis, Insights and Forecast - by Indication
- 8.3.1. Lung Cancer
- 8.3.2. Colorectal Cancer
- 8.3.3. Melanoma
- 8.3.4. Other Cancers
- 8.1. Market Analysis, Insights and Forecast - by Product
- 9. Middle East and Africa Immuno Oncology Assays Industry Analysis, Insights and Forecast, 2020-2032
- 9.1. Market Analysis, Insights and Forecast - by Product
- 9.1.1. Reagents and Antibodies
- 9.1.2. Instruments
- 9.1.3. Software
- 9.1.4. Consumables and Accessories
- 9.2. Market Analysis, Insights and Forecast - by Technology
- 9.2.1. Immunoassay
- 9.2.2. PCR
- 9.2.3. NGS
- 9.2.4. Flow Cytometry
- 9.2.5. Other Technologies
- 9.3. Market Analysis, Insights and Forecast - by Indication
- 9.3.1. Lung Cancer
- 9.3.2. Colorectal Cancer
- 9.3.3. Melanoma
- 9.3.4. Other Cancers
- 9.1. Market Analysis, Insights and Forecast - by Product
- 10. South America Immuno Oncology Assays Industry Analysis, Insights and Forecast, 2020-2032
- 10.1. Market Analysis, Insights and Forecast - by Product
- 10.1.1. Reagents and Antibodies
- 10.1.2. Instruments
- 10.1.3. Software
- 10.1.4. Consumables and Accessories
- 10.2. Market Analysis, Insights and Forecast - by Technology
- 10.2.1. Immunoassay
- 10.2.2. PCR
- 10.2.3. NGS
- 10.2.4. Flow Cytometry
- 10.2.5. Other Technologies
- 10.3. Market Analysis, Insights and Forecast - by Indication
- 10.3.1. Lung Cancer
- 10.3.2. Colorectal Cancer
- 10.3.3. Melanoma
- 10.3.4. Other Cancers
- 10.1. Market Analysis, Insights and Forecast - by Product
- 11. Competitive Analysis
- 11.1. Global Market Share Analysis 2025
- 11.2. Company Profiles
- 11.2.1 Merck KGaA
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Financials (Based on Availability)
- 11.2.2 F Hoffmann-La Roche Ltd
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Financials (Based on Availability)
- 11.2.3 HTG Molecular Diagnostics Inc
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Financials (Based on Availability)
- 11.2.4 Agilent Technologies Inc
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Financials (Based on Availability)
- 11.2.5 Crown Bioscience
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Financials (Based on Availability)
- 11.2.6 PerkinElmer Inc
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Financials (Based on Availability)
- 11.2.7 Illumina Inc
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Financials (Based on Availability)
- 11.2.8 Thermo Fisher Scientific
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Financials (Based on Availability)
- 11.2.9 InSphero
- 11.2.9.1. Overview
- 11.2.9.2. Products
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Financials (Based on Availability)
- 11.2.1 Merck KGaA
List of Figures
- Figure 1: Global Immuno Oncology Assays Industry Revenue Breakdown (billion, %) by Region 2025 & 2033
- Figure 2: Global Immuno Oncology Assays Industry Volume Breakdown (K Unit, %) by Region 2025 & 2033
- Figure 3: North America Immuno Oncology Assays Industry Revenue (billion), by Product 2025 & 2033
- Figure 4: North America Immuno Oncology Assays Industry Volume (K Unit), by Product 2025 & 2033
- Figure 5: North America Immuno Oncology Assays Industry Revenue Share (%), by Product 2025 & 2033
- Figure 6: North America Immuno Oncology Assays Industry Volume Share (%), by Product 2025 & 2033
- Figure 7: North America Immuno Oncology Assays Industry Revenue (billion), by Technology 2025 & 2033
- Figure 8: North America Immuno Oncology Assays Industry Volume (K Unit), by Technology 2025 & 2033
- Figure 9: North America Immuno Oncology Assays Industry Revenue Share (%), by Technology 2025 & 2033
- Figure 10: North America Immuno Oncology Assays Industry Volume Share (%), by Technology 2025 & 2033
- Figure 11: North America Immuno Oncology Assays Industry Revenue (billion), by Indication 2025 & 2033
- Figure 12: North America Immuno Oncology Assays Industry Volume (K Unit), by Indication 2025 & 2033
- Figure 13: North America Immuno Oncology Assays Industry Revenue Share (%), by Indication 2025 & 2033
- Figure 14: North America Immuno Oncology Assays Industry Volume Share (%), by Indication 2025 & 2033
- Figure 15: North America Immuno Oncology Assays Industry Revenue (billion), by Country 2025 & 2033
- Figure 16: North America Immuno Oncology Assays Industry Volume (K Unit), by Country 2025 & 2033
- Figure 17: North America Immuno Oncology Assays Industry Revenue Share (%), by Country 2025 & 2033
- Figure 18: North America Immuno Oncology Assays Industry Volume Share (%), by Country 2025 & 2033
- Figure 19: Europe Immuno Oncology Assays Industry Revenue (billion), by Product 2025 & 2033
- Figure 20: Europe Immuno Oncology Assays Industry Volume (K Unit), by Product 2025 & 2033
- Figure 21: Europe Immuno Oncology Assays Industry Revenue Share (%), by Product 2025 & 2033
- Figure 22: Europe Immuno Oncology Assays Industry Volume Share (%), by Product 2025 & 2033
- Figure 23: Europe Immuno Oncology Assays Industry Revenue (billion), by Technology 2025 & 2033
- Figure 24: Europe Immuno Oncology Assays Industry Volume (K Unit), by Technology 2025 & 2033
- Figure 25: Europe Immuno Oncology Assays Industry Revenue Share (%), by Technology 2025 & 2033
- Figure 26: Europe Immuno Oncology Assays Industry Volume Share (%), by Technology 2025 & 2033
- Figure 27: Europe Immuno Oncology Assays Industry Revenue (billion), by Indication 2025 & 2033
- Figure 28: Europe Immuno Oncology Assays Industry Volume (K Unit), by Indication 2025 & 2033
- Figure 29: Europe Immuno Oncology Assays Industry Revenue Share (%), by Indication 2025 & 2033
- Figure 30: Europe Immuno Oncology Assays Industry Volume Share (%), by Indication 2025 & 2033
- Figure 31: Europe Immuno Oncology Assays Industry Revenue (billion), by Country 2025 & 2033
- Figure 32: Europe Immuno Oncology Assays Industry Volume (K Unit), by Country 2025 & 2033
- Figure 33: Europe Immuno Oncology Assays Industry Revenue Share (%), by Country 2025 & 2033
- Figure 34: Europe Immuno Oncology Assays Industry Volume Share (%), by Country 2025 & 2033
- Figure 35: Asia Pacific Immuno Oncology Assays Industry Revenue (billion), by Product 2025 & 2033
- Figure 36: Asia Pacific Immuno Oncology Assays Industry Volume (K Unit), by Product 2025 & 2033
- Figure 37: Asia Pacific Immuno Oncology Assays Industry Revenue Share (%), by Product 2025 & 2033
- Figure 38: Asia Pacific Immuno Oncology Assays Industry Volume Share (%), by Product 2025 & 2033
- Figure 39: Asia Pacific Immuno Oncology Assays Industry Revenue (billion), by Technology 2025 & 2033
- Figure 40: Asia Pacific Immuno Oncology Assays Industry Volume (K Unit), by Technology 2025 & 2033
- Figure 41: Asia Pacific Immuno Oncology Assays Industry Revenue Share (%), by Technology 2025 & 2033
- Figure 42: Asia Pacific Immuno Oncology Assays Industry Volume Share (%), by Technology 2025 & 2033
- Figure 43: Asia Pacific Immuno Oncology Assays Industry Revenue (billion), by Indication 2025 & 2033
- Figure 44: Asia Pacific Immuno Oncology Assays Industry Volume (K Unit), by Indication 2025 & 2033
- Figure 45: Asia Pacific Immuno Oncology Assays Industry Revenue Share (%), by Indication 2025 & 2033
- Figure 46: Asia Pacific Immuno Oncology Assays Industry Volume Share (%), by Indication 2025 & 2033
- Figure 47: Asia Pacific Immuno Oncology Assays Industry Revenue (billion), by Country 2025 & 2033
- Figure 48: Asia Pacific Immuno Oncology Assays Industry Volume (K Unit), by Country 2025 & 2033
- Figure 49: Asia Pacific Immuno Oncology Assays Industry Revenue Share (%), by Country 2025 & 2033
- Figure 50: Asia Pacific Immuno Oncology Assays Industry Volume Share (%), by Country 2025 & 2033
- Figure 51: Middle East and Africa Immuno Oncology Assays Industry Revenue (billion), by Product 2025 & 2033
- Figure 52: Middle East and Africa Immuno Oncology Assays Industry Volume (K Unit), by Product 2025 & 2033
- Figure 53: Middle East and Africa Immuno Oncology Assays Industry Revenue Share (%), by Product 2025 & 2033
- Figure 54: Middle East and Africa Immuno Oncology Assays Industry Volume Share (%), by Product 2025 & 2033
- Figure 55: Middle East and Africa Immuno Oncology Assays Industry Revenue (billion), by Technology 2025 & 2033
- Figure 56: Middle East and Africa Immuno Oncology Assays Industry Volume (K Unit), by Technology 2025 & 2033
- Figure 57: Middle East and Africa Immuno Oncology Assays Industry Revenue Share (%), by Technology 2025 & 2033
- Figure 58: Middle East and Africa Immuno Oncology Assays Industry Volume Share (%), by Technology 2025 & 2033
- Figure 59: Middle East and Africa Immuno Oncology Assays Industry Revenue (billion), by Indication 2025 & 2033
- Figure 60: Middle East and Africa Immuno Oncology Assays Industry Volume (K Unit), by Indication 2025 & 2033
- Figure 61: Middle East and Africa Immuno Oncology Assays Industry Revenue Share (%), by Indication 2025 & 2033
- Figure 62: Middle East and Africa Immuno Oncology Assays Industry Volume Share (%), by Indication 2025 & 2033
- Figure 63: Middle East and Africa Immuno Oncology Assays Industry Revenue (billion), by Country 2025 & 2033
- Figure 64: Middle East and Africa Immuno Oncology Assays Industry Volume (K Unit), by Country 2025 & 2033
- Figure 65: Middle East and Africa Immuno Oncology Assays Industry Revenue Share (%), by Country 2025 & 2033
- Figure 66: Middle East and Africa Immuno Oncology Assays Industry Volume Share (%), by Country 2025 & 2033
- Figure 67: South America Immuno Oncology Assays Industry Revenue (billion), by Product 2025 & 2033
- Figure 68: South America Immuno Oncology Assays Industry Volume (K Unit), by Product 2025 & 2033
- Figure 69: South America Immuno Oncology Assays Industry Revenue Share (%), by Product 2025 & 2033
- Figure 70: South America Immuno Oncology Assays Industry Volume Share (%), by Product 2025 & 2033
- Figure 71: South America Immuno Oncology Assays Industry Revenue (billion), by Technology 2025 & 2033
- Figure 72: South America Immuno Oncology Assays Industry Volume (K Unit), by Technology 2025 & 2033
- Figure 73: South America Immuno Oncology Assays Industry Revenue Share (%), by Technology 2025 & 2033
- Figure 74: South America Immuno Oncology Assays Industry Volume Share (%), by Technology 2025 & 2033
- Figure 75: South America Immuno Oncology Assays Industry Revenue (billion), by Indication 2025 & 2033
- Figure 76: South America Immuno Oncology Assays Industry Volume (K Unit), by Indication 2025 & 2033
- Figure 77: South America Immuno Oncology Assays Industry Revenue Share (%), by Indication 2025 & 2033
- Figure 78: South America Immuno Oncology Assays Industry Volume Share (%), by Indication 2025 & 2033
- Figure 79: South America Immuno Oncology Assays Industry Revenue (billion), by Country 2025 & 2033
- Figure 80: South America Immuno Oncology Assays Industry Volume (K Unit), by Country 2025 & 2033
- Figure 81: South America Immuno Oncology Assays Industry Revenue Share (%), by Country 2025 & 2033
- Figure 82: South America Immuno Oncology Assays Industry Volume Share (%), by Country 2025 & 2033
List of Tables
- Table 1: Global Immuno Oncology Assays Industry Revenue billion Forecast, by Product 2020 & 2033
- Table 2: Global Immuno Oncology Assays Industry Volume K Unit Forecast, by Product 2020 & 2033
- Table 3: Global Immuno Oncology Assays Industry Revenue billion Forecast, by Technology 2020 & 2033
- Table 4: Global Immuno Oncology Assays Industry Volume K Unit Forecast, by Technology 2020 & 2033
- Table 5: Global Immuno Oncology Assays Industry Revenue billion Forecast, by Indication 2020 & 2033
- Table 6: Global Immuno Oncology Assays Industry Volume K Unit Forecast, by Indication 2020 & 2033
- Table 7: Global Immuno Oncology Assays Industry Revenue billion Forecast, by Region 2020 & 2033
- Table 8: Global Immuno Oncology Assays Industry Volume K Unit Forecast, by Region 2020 & 2033
- Table 9: Global Immuno Oncology Assays Industry Revenue billion Forecast, by Product 2020 & 2033
- Table 10: Global Immuno Oncology Assays Industry Volume K Unit Forecast, by Product 2020 & 2033
- Table 11: Global Immuno Oncology Assays Industry Revenue billion Forecast, by Technology 2020 & 2033
- Table 12: Global Immuno Oncology Assays Industry Volume K Unit Forecast, by Technology 2020 & 2033
- Table 13: Global Immuno Oncology Assays Industry Revenue billion Forecast, by Indication 2020 & 2033
- Table 14: Global Immuno Oncology Assays Industry Volume K Unit Forecast, by Indication 2020 & 2033
- Table 15: Global Immuno Oncology Assays Industry Revenue billion Forecast, by Country 2020 & 2033
- Table 16: Global Immuno Oncology Assays Industry Volume K Unit Forecast, by Country 2020 & 2033
- Table 17: United States Immuno Oncology Assays Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 18: United States Immuno Oncology Assays Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 19: Canada Immuno Oncology Assays Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 20: Canada Immuno Oncology Assays Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 21: Mexico Immuno Oncology Assays Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 22: Mexico Immuno Oncology Assays Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 23: Global Immuno Oncology Assays Industry Revenue billion Forecast, by Product 2020 & 2033
- Table 24: Global Immuno Oncology Assays Industry Volume K Unit Forecast, by Product 2020 & 2033
- Table 25: Global Immuno Oncology Assays Industry Revenue billion Forecast, by Technology 2020 & 2033
- Table 26: Global Immuno Oncology Assays Industry Volume K Unit Forecast, by Technology 2020 & 2033
- Table 27: Global Immuno Oncology Assays Industry Revenue billion Forecast, by Indication 2020 & 2033
- Table 28: Global Immuno Oncology Assays Industry Volume K Unit Forecast, by Indication 2020 & 2033
- Table 29: Global Immuno Oncology Assays Industry Revenue billion Forecast, by Country 2020 & 2033
- Table 30: Global Immuno Oncology Assays Industry Volume K Unit Forecast, by Country 2020 & 2033
- Table 31: Germany Immuno Oncology Assays Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 32: Germany Immuno Oncology Assays Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 33: United Kingdom Immuno Oncology Assays Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 34: United Kingdom Immuno Oncology Assays Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 35: France Immuno Oncology Assays Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 36: France Immuno Oncology Assays Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 37: Italy Immuno Oncology Assays Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 38: Italy Immuno Oncology Assays Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 39: Spain Immuno Oncology Assays Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 40: Spain Immuno Oncology Assays Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 41: Rest of Europe Immuno Oncology Assays Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 42: Rest of Europe Immuno Oncology Assays Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 43: Global Immuno Oncology Assays Industry Revenue billion Forecast, by Product 2020 & 2033
- Table 44: Global Immuno Oncology Assays Industry Volume K Unit Forecast, by Product 2020 & 2033
- Table 45: Global Immuno Oncology Assays Industry Revenue billion Forecast, by Technology 2020 & 2033
- Table 46: Global Immuno Oncology Assays Industry Volume K Unit Forecast, by Technology 2020 & 2033
- Table 47: Global Immuno Oncology Assays Industry Revenue billion Forecast, by Indication 2020 & 2033
- Table 48: Global Immuno Oncology Assays Industry Volume K Unit Forecast, by Indication 2020 & 2033
- Table 49: Global Immuno Oncology Assays Industry Revenue billion Forecast, by Country 2020 & 2033
- Table 50: Global Immuno Oncology Assays Industry Volume K Unit Forecast, by Country 2020 & 2033
- Table 51: China Immuno Oncology Assays Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 52: China Immuno Oncology Assays Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 53: Japan Immuno Oncology Assays Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 54: Japan Immuno Oncology Assays Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 55: India Immuno Oncology Assays Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 56: India Immuno Oncology Assays Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 57: Australia Immuno Oncology Assays Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 58: Australia Immuno Oncology Assays Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 59: South Korea Immuno Oncology Assays Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 60: South Korea Immuno Oncology Assays Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 61: Rest of Asia Pacific Immuno Oncology Assays Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 62: Rest of Asia Pacific Immuno Oncology Assays Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 63: Global Immuno Oncology Assays Industry Revenue billion Forecast, by Product 2020 & 2033
- Table 64: Global Immuno Oncology Assays Industry Volume K Unit Forecast, by Product 2020 & 2033
- Table 65: Global Immuno Oncology Assays Industry Revenue billion Forecast, by Technology 2020 & 2033
- Table 66: Global Immuno Oncology Assays Industry Volume K Unit Forecast, by Technology 2020 & 2033
- Table 67: Global Immuno Oncology Assays Industry Revenue billion Forecast, by Indication 2020 & 2033
- Table 68: Global Immuno Oncology Assays Industry Volume K Unit Forecast, by Indication 2020 & 2033
- Table 69: Global Immuno Oncology Assays Industry Revenue billion Forecast, by Country 2020 & 2033
- Table 70: Global Immuno Oncology Assays Industry Volume K Unit Forecast, by Country 2020 & 2033
- Table 71: GCC Immuno Oncology Assays Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 72: GCC Immuno Oncology Assays Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 73: South Africa Immuno Oncology Assays Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 74: South Africa Immuno Oncology Assays Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 75: Rest of Middle East and Africa Immuno Oncology Assays Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 76: Rest of Middle East and Africa Immuno Oncology Assays Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 77: Global Immuno Oncology Assays Industry Revenue billion Forecast, by Product 2020 & 2033
- Table 78: Global Immuno Oncology Assays Industry Volume K Unit Forecast, by Product 2020 & 2033
- Table 79: Global Immuno Oncology Assays Industry Revenue billion Forecast, by Technology 2020 & 2033
- Table 80: Global Immuno Oncology Assays Industry Volume K Unit Forecast, by Technology 2020 & 2033
- Table 81: Global Immuno Oncology Assays Industry Revenue billion Forecast, by Indication 2020 & 2033
- Table 82: Global Immuno Oncology Assays Industry Volume K Unit Forecast, by Indication 2020 & 2033
- Table 83: Global Immuno Oncology Assays Industry Revenue billion Forecast, by Country 2020 & 2033
- Table 84: Global Immuno Oncology Assays Industry Volume K Unit Forecast, by Country 2020 & 2033
- Table 85: Brazil Immuno Oncology Assays Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 86: Brazil Immuno Oncology Assays Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 87: Argentina Immuno Oncology Assays Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 88: Argentina Immuno Oncology Assays Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 89: Rest of South America Immuno Oncology Assays Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 90: Rest of South America Immuno Oncology Assays Industry Volume (K Unit) Forecast, by Application 2020 & 2033
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the Immuno Oncology Assays Industry?
The projected CAGR is approximately 11.8%.
2. Which companies are prominent players in the Immuno Oncology Assays Industry?
Key companies in the market include Merck KGaA, F Hoffmann-La Roche Ltd, HTG Molecular Diagnostics Inc , Agilent Technologies Inc, Crown Bioscience, PerkinElmer Inc, Illumina Inc, Thermo Fisher Scientific, InSphero.
3. What are the main segments of the Immuno Oncology Assays Industry?
The market segments include Product, Technology, Indication.
4. Can you provide details about the market size?
The market size is estimated to be USD 6.3 billion as of 2022.
5. What are some drivers contributing to market growth?
Rising Incidence of Cancer Globally; Increasing Adoption of Targeted Therapy.
6. What are the notable trends driving market growth?
Immunoassay Segment is Expected to Have Significant Share in the Market Over the Forecast Period.
7. Are there any restraints impacting market growth?
Unfavorable Regulatory and Reimbursement Scenario.
8. Can you provide examples of recent developments in the market?
September 2022: The US FDA approved Thermo Fisher Scientific's Oncomine Dx Target Test as a companion diagnostic (CDx) aid in selecting patients. They do it with the help of RET-fusion positive locally advanced or metastatic non-small cell lung cancer (NSCLC), RET-fusion positive advanced or metastatic thyroid cancer, and RET-mutation positive advanced or metastatic medullary thyroid cancer (MTC) who may be eligible for treatment with Lilly's Retevmo (selpercatinib).
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4750, USD 5250, and USD 8750 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in billion and volume, measured in K Unit.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "Immuno Oncology Assays Industry," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the Immuno Oncology Assays Industry report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the Immuno Oncology Assays Industry?
To stay informed about further developments, trends, and reports in the Immuno Oncology Assays Industry, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence